Reza Razeghinejad is an Ophthalmology physician affiliated with Thomas Jefferson University. OpenAlex indexes 213 publications with 2,991 citations (h-index 30); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
840 Walnut St Ste 1110
Philadelphia, PA 191075109
Telephone
215-928-3197Registry record last updated 6 Nov 2019.
Clinical trials
- Evaluating Home Testing Devices for the Management of Glaucoma
Sponsor: Wills Eye
- Caffeine Consumption in Glaucoma Patients and Healthy Subjects
Sponsor: Wills Eye
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20251 payment
- NEW WORLD MEDICAL,INC.Program year20251 payment
- Alcon Vision LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
86.9%Prostaglandin Analog30.2%Latanoprost80%Lumigan12%Travoprost6%Tafluprost1%Iyuzeh1%Zioptan1%Bimatoprost1%Part D<11 patientsCarbonic Anhydrase Inhibitor26.9%Dorzolamide-Timolol66%Dorzolamide Hcl20%Simbrinza7%Acetazolamide3%Brinzolamide3%Acetazolamide Er1%Azopt1%Part D<11 patients+ 6 more classes in this area
Cardiovascular
6.8%Beta blocker6.8%Timolol Maleate100%Part D<11 patientsAnti-infectives
2.6%Macrolide1.5%Erythromycin100%Part D≥50 patientsFluoroquinolone Antibacterial1.2%Moxifloxacin100%Part D≥54 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- GLP-1 Receptor Agonists Use and Incidence of Glaucoma: A Systematic Review and Meta-Analysis
American Journal of Ophthalmology
2024 - iStent versus iStent inject implantation combined with phacoemulsification in open angle glaucoma
Indian Journal of Ophthalmology
2021 - Pathophysiology and management of glaucoma and ocular hypertension related to trauma
Survey of Ophthalmology
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Carol Shields, MD
Thomas Jefferson University
Joseph Bavaria, MD
Thomas Jefferson University
Michele Meltzer, MD
Thomas Jefferson University
Marinos Dalakas, MD
Thomas Jefferson University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”